Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Francis, Arhin"'
Autor:
Mark Wise, Dr., Francis Arhin, Dr., Gregory Stone, Dr., Meredith Hackel, Dr., Daniel Sahm, Dr.
Publikováno v:
Journal of Global Antimicrobial Resistance, Vol 31, Iss , Pp S13-S14 (2022)
Externí odkaz:
https://doaj.org/article/28f885997eca4fa28ed7b485ead977e9
Publikováno v:
Journal of Global Antimicrobial Resistance, Vol 31, Iss , Pp S12-S13 (2022)
Externí odkaz:
https://doaj.org/article/5734e5f513ea4663b81bcbba6eefd2dd
Publikováno v:
Open Forum Infectious Diseases. 9
Background The rapid spread of antimicrobial resistance among clinically isolated Enterobacterales (Eba) continues to threaten public health. Aztreonam (ATM) is a monobactam stable to hydrolysis by metallo-β-lactamases (MBLs) and avibactam (AVI) inh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a7b0b480e76f418d74801bc6b486b1b7
https://doi.org/10.1093/ofid/ofac492.1347
https://doi.org/10.1093/ofid/ofac492.1347
Publikováno v:
Open Forum Infectious Diseases. 9
Background β-lactamase-producing Enterobacterales (Eba) frequently carry resistance mechanisms for multiple drug classes, limiting treatment options. Avibactam (AVI) inhibits class A, class C, and some class D serine β-lactamases, while aztreonam (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b28b1c6ea71fb326c8879b720d9f0e15
https://doi.org/10.1093/ofid/ofac492.1350
https://doi.org/10.1093/ofid/ofac492.1350
Publikováno v:
Open Forum Infectious Diseases
Background Treatment options for β-lactamase-producing Enterobacterales are limited, particularly for infections caused by metallo-β-lactamase (MBL)-producing strains. The β-lactam/non-β-lactam β-lactamase inhibitor combination aztreonam-avibact
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7aac7fd1bd9be1d949761fb08cb3af07
http://europepmc.org/articles/PMC8644430
http://europepmc.org/articles/PMC8644430
Publikováno v:
Open Forum Infectious Diseases
Background Elevated resistance rates have been reported in ICUs. Aztreonam (ATM) combined with avibactam (AVI) is being developed for use against drug-resistant Enterobacterales (Ebact), including metallo-β-lactamase (MBL)-positive isolates. We exam
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5184abc1f868f571ac1cd2fb2a6c0150
http://europepmc.org/articles/PMC8644095
http://europepmc.org/articles/PMC8644095
Autor:
Francis, Arhin, Odette, Bélanger, Stéphane, Ciblat, Mohammed, Dehbi, Daniel, Delorme, Evelyne, Dietrich, Dilip, Dixit, Yanick, Lafontaine, Dario, Lehoux, Jing, Liu, Geoffrey A, McKay, Greg, Moeck, Ranga, Reddy, Yannick, Rose, Ramakrishnan, Srikumar, Kelly S E, Tanaka, Daniel M, Williams, Philippe, Gros, Jerry, Pelletier, Thomas R, Parr, Adel Rafai, Far
Publikováno v:
Bioorganicmedicinal chemistry. 14(17)
The RNA polymerase holoenzyme is a proven target for antibacterial agents. A high-throughput screening program based on this enzyme from Staphylococcus aureus had previously identified a 2-ureidothiophene-3-carboxylate as a low micromolar inhibitor.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::98209a7c5a9bda3e658ad9cb8529f1f8
https://pubmed.ncbi.nlm.nih.gov/16759869
https://pubmed.ncbi.nlm.nih.gov/16759869